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Purpose: According to the WHO vancomycin-resistant Enterococcus faecium (VRE) belongs 
to the microorganisms for which new antibiotics are urgently needed. Depending on the type 
of vancomycin resistance vanA gene VRE is differentiated from vanB VRE and other types. 
In this retrospective analysis the results of VRE surveillance performed at a German tertiary 
hospital with approximately 1,200 beds between 2013 and 2017 are shown.
Patients and methods: Rectal screening swabs were taken at admission and once 
per week on the early rehabilitation ward of Ingolstadt Hospital (ERWIN) but not at other 
wards. The number of VRE colonized patients was evaluated by using appropriate computer 
software (LabCentre, Hybase). The Hybase program was also used to find out the number of 
Saccharomyces boulardii and multi-susceptible Escherichia coli Nissle in blood cultures of 
patients at ERWIN. The mechanism of vancomycin resistance was examined by PCR and 
clonality of VRE strains was analyzed by pulsed-field gel electrophoresis.
Results: Between 2013 and 2015 the number of VRE increased from 30 to 78 per year whereas 
in 2016 and 2017 the number declined to 51. Systematic analysis of the laboratory data revealed 
that this increase was driven by oligoclonal transmission of vanB VRE on ERWIN until August 
2016 despite performing intensified infection control measures. However, afterward the number 
of VRE decreased at ERWIN and subsequently at the other wards. While searching for the 
reason behind this beneficial development we noticed that at ERWIN, patients treated with 
antibiotics received two probiotic medications simultaneously (S. boulardii, E. coli Nissle) for 
the duration of the antibiotic therapy plus an additional 2 days. There was no indication of side 
effects caused by these microorganisms, particularly no infections.
Conclusion: Application of S. boulardii and E. coli Nissle was safe and associated with reduced 
transmission of VRE from patient to patient at ERWIN. Therefore, in our setting, probiotic 
treatment of patients receiving antibiotics contributed to the increase of patients’ safety.
Keywords: microbiota, oligoclonal spread, outbreak, probiotics, vanB, bacterial spread, circuit 
model of bacterial transmission, vanA 
Introduction
Probiotics are live microorganisms that render beneficial effects once consumed. While 
in obese individuals probiotics seem favorable for losing weight, their usage was 
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controversially discussed for the treatment of various diseases, 
including inflammatory bowel diseases, Clostridium difficile 
infections, and allergic diseases.1–5 Apart from mediating ben-
eficial effects, probiotics themselves should not cause disad-
vantageous effects, in particular not infections. A multitude of 
microorganisms have been used, among them lactobacilli, bifi-
dobacteria, Streptococcus (ie, Streptococcus thermophiles), 
Escherichia coli Nissle, and Saccharomyces boulardii.2,6–9
S. boulardii exhibits anti-inflammatory capacities and 
inhibits binding of pathogenic bacteria to the epithelium.10 
Similar effects were described following application of 
E. coli Nissle.9 In clinical settings S. boulardii reduced the 
development of antibiotic-associated diarrhea including 
diarrhea caused by C. difficile.11
In 2018 the WHO updated the list indexing bacterial 
species for which new antibiotics are urgently needed, among 
them vancomycin-resistant Enterococcus faecium (VRE).12 
Within the past years nosocomial spread of VRE has occurred 
with increasing frequency.13,14 Fortunately, the bacteria often 
causes colonization but not infections.15 However, infections 
in severely ill patients who frequently receive antibiotic 
treatment have become more common, contributing to a rise 
in fatal outcomes and increased hospital costs.14,16–18
Eight genes mediating vancomycin resistance have been 
described of which vanA and vanB are relevant in clinical prac-
tice. In laboratory tests vanA VRE is resistant to vancomycin 
and teicoplanin while vanB VRE is susceptible to teicoplanin. 
Apart from glycopeptide resistance, VRE often contains vari-
ous pathogenicity factors, eg, the enterococcal surface protein 
and hyaluronidase encoded by the genes esp and hyl. The esp 
gene resides on an E. faecium pathogenicity island as part of 
the chromosome in hospital-associated strain types, whereas 
the so-called hyl
Efm
 gene is part of another set of mobile genetic 
elements mainly residing on an E. faecium megaplasmid.19,20
In the present study, we report the results of the 
surveillance of multi-resistant bacteria in a tertiary care 
hospital in Germany. This observational study focused on 
the epidemiology of VRE in an early rehabilitation ward.
Patients and methods
Ingolstadt Hospital is a tertiary care hospital with approxi-
mately 1,200 beds located in the center of Bavaria (South-
East Germany). The hospital contains an early rehabilitation 
ward. Characteristics of the ward have been described 
earlier in detail.21,22 In brief, the early rehabilitation ward 
of  Ingolstadt Hospital (ERWIN) has 22 beds. Patients pre-
dominantly suffer from neurological deficits (mostly stroke) 
and trauma (at least two injuries). Due to an outbreak of 
carbapenem-resistant Klebsiella pneumoniae (CKP) in the 
winter of 2015, ERWIN was closed for several weeks.21 After 
intensively cleaning and disinfecting the ward, ERWIN was 
reopened in week 8 of 2015 (February 2015).
A time line showing the measures most likely influencing 
VRE incidence is shown in Figure 1.
Between May 2014 and November 2016 rectal swabs 
were taken from each patient treated at ERWIN at admis-
sion and once per week to identify colonization with VRE. 
The first VRE isolate of each patient was systematically 
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Figure 1 Observation period and chronological sequence of measures performed at eRWin probably contributing to the incidence of VRe. 
Notes: in the winter of 2015 the ward was closed for several weeks (black bar) due to an outbreak of carbapenem-resistant Klebsiella pneumoniae. afterward iCM were 
intensified. Application of probiotics was started in September 2015.
Abbreviations: ERWIN, early rehabilitation ward of Ingolstadt Hospital; ICM, infection control measures; PFGE, pulsed-field gel electrophoresis; RKI, Robert Koch Institute; 
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sent to the German Reference Centre for Staphylococci and 
Enterococci at the Robert Koch Institute (RKI).
In the hospital, patients colonized/infected with VRE 
either resided in a single room or underwent cohort isolation 
with a sex-matched VRE colonized room-mate. Staff and 
visitors in contact with VRE colonized patients wore gloves 
and coats and were instructed to consistently maintain basic 
hygiene measures, primarily hand disinfection. However, 
exceptions occurred when a colonized patient suffered 
extremely from isolation and consequently standard infection 
control measures were performed. Before the CKP outbreak 
these exceptions were also allowed at ERWIN but not after 
reopening the ward in February 2015.
Starting in September 2015 patients at ERWIN received 
two probiotic drugs while receiving antibiotics. Probiotics 
were S. boulardii 375 mg/hard capsule, (Eubiol; CNP-
Pharma GmbH, Fürstenzell, Germany) and E. coli Nissle 
2.5–25×109 bacteria/capsule (Mutaflor; Ardeypharm GmbH, 
Herdecke, Germany). S. boulardii was given once a day 
(1-0-0) and E. coli Nissle twice a day (1-0-1). Probiotics were 
applied during antibiotic treatment and for and additional 
2 days. Probiotics were not systematically applied to patients 
on the other wards in the hospital.
The laboratory in Ingolstadt Hospital performed diagnostic 
microbiology as described earlier.21,23 In brief, species’ identi-
fication and antibiotic susceptibility were examined with the 
Vitek 2 compact (BioMerieux, Nürtingen, Germany). VRE 
from screening swabs was cultured on a selective agar plate 
(Brilliance VRE agar; Oxoid, Wesel, Germany). Vancomycin 
resistance was confirmed by Etest analysis (Biomerieux). Mini-
mal inhibitory concentration #4 mg/L for vancomycin was 
considered as susceptible. Proof of VRE was communicated 
by the laboratory staff to the physicians treating the patients 
and also to the Department of Infectious Diseases and Infec-
tion Control. The results of microbiological analyses were 
sent to the computer program Hybase (EpiNetAG, Bochum, 
Germany). This program allows the identification of patients 
colonized/infected with a certain bacterium. In our setting E. 
faecium and E. faecium VRE were encoded as two different 
species. This allowed easy access and fast identification of 
VRE colonized patients and the date of bacterial isolation 
in a certain period, eg, 2013–2017 by using the Hybase pro-
gram. Negative screening results of VRE colonized patients 
were obtained with the laboratory software LabCentre l.i.c. 
(i-SOLUTION Health GmbH, Mannheim, Germany). Num-
ber of patient days were received from the computer program 
industry solutions health care module (SAP/IS-H; Siemens, 
Munich, Germany), adapted to the requirements of the hospital.
The standard analysis portfolio at the RKI contained an 
extended antibiotic susceptibility testing of 18 substances by 
broth microdilution and using European Committee on Anti-
microbial Susceptibility Testing recommendations and criteria 
(EUCAST clinical breakpoints version 7.0; in case of missing 
breakpoints the corresponding epidemiological cut-off value 
was used for a classification susceptible [S]-intermediate [I]-
resistant [R]). Genomic DNA was isolated using a DNeasy 
Blood and Tissue Kit (Qiagen Hilden,  Germany) and markers 
vanA and vanB as well as esp and hyl were amplified in two 
separate multiplex PCRs as described elsewhere.20,24
For pulsed-field gel electrophoresis (PFGE), bacterial 
cells were fixed in agarose plugs and DNA was extracted 
using a standard protocol.24 SmaI-digested genomic DNA 
was resolved in an agarose gel in an alternating electric 
field provided in a CHEF III PFGE apparatus (Bio-Rad 
Laboratories Inc., Hercules, CA, USA). Band patterns were 
analyzed using BioNumerics version 7.6 (Applied Maths, 
Sint-Martens-Latem, Belgium) with the following settings: 
optimization 0.5 and position tolerance 1.0.
Data about hand disinfection practices were obtained 
from the purchasing department of the hospital. When a 
bottle of hand disinfectant was empty or had reached the 
date of expiration the cleaning assistants replaced it with a 
new bottle. The cleaning assistants also assigned this replace-
ment to a particular cost center. However, due to the fact 
that two wards form a spatial unit, these assignments were 
not very reliable. Therefore, hand disinfectant consumption 
was recorded for a unit consisting of two wards, respectively. 
Volume of consumed hand disinfectant was related to the 
number of patient days. Number of patient days on ERWIN 
and the neighboring palliative ward, as well as the number of 
patient days of all wards were obtained from the controlling 
department (Figure S1).
Ethics statement 
The study does not contain clinical studies or patient data 
allowing identification of patients or individual clinical 
course. According to the ethics committee of the Bavarian 
Medical Association (Bayerische Landesärztekammer), 
which has jurisdiction over medical matters in our state 
(Federal State Bavaria), ethics approval was not necessary 
for this analysis. This study was conducted in accordance 
with the Declaration of Helsinki.
Results
In order to perform surveillance of multi-resistant bacteria in 
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between 2013 and 2017 were retrospectively examined. As 
shown by Figure 2, in 2013, 23 patients had been colonized 
with VRE. In 2015 this number increased to 78 while in 2016 
and 2017 it declined to 51, respectively. From 2013–2014 
at ERWIN the number of VRE colonized patients increased 
from four to 27 and remained high in 2015 (N=29) and 2016 
(N=26). As shown by Table 1, incidence at ERWIN increased 
up to 32 times higher than that of the other wards. As the 
VRE burden of ERWIN appeared similar between 2014 and 
2016, it seems that the situation at ERWIN had not changed 
within this period.
However, this impression changed when the number of 
VRE colonized patients identified within a certain month and 
also the genotype of glycopeptide resistance were considered 
(Figure 3). VRE exhibiting vanA-encoded resistance was 
only sporadically isolated between 2013 and 2016. However, 
the number of vanA VRE markedly increased within the last 
quarter of 2016, especially due to the fact that in October and 
November 2016 an outbreak occurred at ERWIN (Figure 3A), 
supposedly affecting eleven patients. Results of PFGE analy-
sis showed that six of the eleven isolates were not identical 
to other isolates, as the corresponding banding patterns were 
unique (Figure 4). Two of the five vanA VRE exhibiting 
an identical banding pattern (cluster 2) had been isolated at 
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Figure 2 absolute number of VRe colonized patients treated at ingolstadt hospital 
per year. 
Abbreviations: eRWin, early rehabilitation ward of ingolstadt hospital; VRe, 
vancomycin-resistant Enterococcus faecium.
Table 1 incidence of VRe per year (2013–2014) per 100,000 
patient days at ingolstadt hospital
 2013 2014 2015 2016 2017
eRWin 55.1 358.5 429.1 396.2 0
all wards including eRWin 11.4 25.1 38.5 24.5 24.4
Wards other than eRWin 9.8 12.5 25.0 12.4 25.2
Abbreviations: eRWin, early rehabilitation ward of ingolstadt hospital; VRe, 
vancomycin-resistant Enterococcus faecium.
had acquired the bacteria earlier. Therefore, at most, three of 
the eleven vanA VRE could have been acquired at ERWIN. 
By performing intensified infection control measures, there 
was no further vanA VRE cases in December 2016.
In contrast to vanA VRE, vanB VRE was rarely 
found in the hospital before December 2013 (Figure 3B). 
However, afterward, the burden of vanB VRE increased, and 
ERWIN was overproportionately affected: from 2014–2016 
50% of all vanB VRE isolated in our hospital had been 
isolated at ERWIN (60/120) and this percentage rose to 
76% (22 of 29) within the period from May–August 2015. 
To normalize VRE burden, the number of VRE colonized 
patients was referred to the number of patient days. As shown 
by Table 1, VRE burden at ERWIN was about tenfold higher 
in comparison to other wards. The tracking of the screening 
results showed that nearly all vanB VRE colonized patients 
treated at ERWIN had acquired VRE colonization in that 
ward (Figure S2). To examine whether vanB VRE was clonal, 
PFGE of vanB VRE isolates was performed. In the winter of 
2015, the ward was closed because of an outbreak of CKP. 
Isolates obtained within the weeks before and after the closure 
were analyzed. As shown by Figure 4, only one of the eleven 
vanB VRE exhibited a unique banding pattern. The other iso-
lates belonged to three distinct clusters (clusters 1, 3, and 4) 
suggesting oligoclonal spread of vanB VRE. VRE belong-
ing to clusters 1 and 4 was isolated before and after the 
closure of ERWIN, indicating presence of an unidentified 
reservoir that persisted, despite extended hygiene measures 
during closure and markedly increased usage of hand disin-
fectant from 2014–2016 (Figure S1). Two of the cluster 3 
VRE colonized patients also exhibited CKP, suggesting an 
association of VRE cluster 3 and CKP transmission.
After August 2015 the number of vanB VRE colonized 
patients decreased, and in the second half of 2016, as well 
as in 2017, VRE colonized patients were not identified at 
ERWIN. As there were no apparent changes in infection 
control measures, neither at the hospital nor at ERWIN, 
the responsible consultant was asked if treatment proce-
dures had been changed. Interestingly, since September 
2015 each patient at ERWIN had received two probiotic 
preparations (E. coli Nissle, S. boulardii) when being treated 
with antibiotics. Probiotics had been applied for the dura-
tion of antibiotic treatment and for an additional 2 days. 
This measure purportedly prevented transmission of vanB 
VRE. Surprisingly, together with the decreased number of 
vanB VRE at ERWIN, this decrease was also observed on 
the other wards of the hospital (Figure S3).
esp was prevalent in more than 90% of VRE. By contrast, 
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Figure 3 number of VRe colonized patients treated at ingolstadt hospital per month.
Notes: (A) number of patients colonized with vana VRe. (B) number of patients colonized with vanB VRe. (C) number of patients colonized with VRe exhibiting unknown 
mechanism of vancomycin resistance.
Abbreviations: eRWin, early rehabilitation ward of ingolstadt hospital; VRe, vancomycin-resistant Enterococcus faecium.
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and 48.3% of vanB VRE isolated from patients at ERWIN 
showed hyl gene as did 66.2% of vanA and 59.7% of vanB 
VRE from patients on other wards (Figure S4). As shown by 
Figure 4, most of the isolates examined by PFGE exhibited 
genes of both pathogenicity factors.
Between 2013 and 2017 VRE was isolated from blood 
cultures of ten patients. Four isolates were vanA and six were 
vanB VRE. One of these vanB VRE patients was treated at 
ERWIN. At ERWIN, eight VRE were isolated from urine 
and a further VRE from ascites. Therefore, the vast majority 
of VRE isolations from patients at ERWIN were colonization 
(Figure S5).
From the patients treated with probiotics, S. boulardii 
was isolated only in stool samples or in swabs taken from 
the throat and notably not in blood cultures. Between 2013 
and 2017 seven blood cultures were found to be positive 
for E. coli. Four cases occurred within the “probiotic 
period” from September 2015–December 2017 (28 months, 
1.74 cases/12 months) and three cases within the preceding 
observation period from January 2013–August 2015 
(32 months, 1.12 cases/12 months) (Figure S6, left panel). 
Analysis of patients’ documents revealed that one of these 
patients had not received probiotics before (Figure S6, right 
panel). Apart from E. coli in blood culture, two patients 
concurrently exhibited E. coli in urine (.100,000/µL) 
suggesting urogenital infection as the cause of blood-stream 
infection and a patient had suffered from perforation of the 
gall bladder before developing blood-stream infection with 
E. coli. In the laboratory, practice does not allow multi-
susceptible bacteria isolated from blood cultures to be stored. 
Therefore, it is not possible from a retrospective standpoint to 
exclude E. coli Nissle as the cause of blood-stream infections 
in three patients. However, as demonstrated previously, this 
seems very unlikely.
Discussion
In this retrospective monocentric analysis we observed that 
the application of two probiotics in patients treated with 
antibiotics was associated with a lower spread of vanB VRE at 
an early rehabilitation ward. On that ward patients underwent 
VRE screening at admission and once per week from May 
2014–November 2016. To examine whether patients had 
been colonized with VRE, rectal swabs were taken from each 
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Figure 4 Results of PFge and PCR analyses of VRe isolated between October 2014 and March 2015 and between October and november 2016. 
Notes: (A) Photograph of PFge typing, and results of PCR analyses. PCR was performed to identify genetic background of vancomycin resistance (vana, vanB) and genes 
of pathogenicity factors (esp and hyl). PFge revealed the presence of three vanB clusters (clusters 1, 3, 4), a vana cluster (cluster 2), and seven unique band patterns. 
(B) isolation of vanB isolates in chronological order between October 2014 and March 2015. *VRe colonized patients also exhibiting carbapenem-resistant Klebsiella 
pneumoniae. (C) isolation of vana isolates in chronological order between October and november 2016. s=VRe exhibiting a unique band pattern in PFge analysis.
Abbreviations: PFGE, pulsed-field gel electrophoresis; VRE, vancomycin-resistant Enterococcus faecium.
hospital. In a US study sensitivity of positive rectal swabs 
depended on the concentration of VRE in feces. As some of 
the patients analyzed in that study exhibited comparably 
low concentrations, sensitivity of rectal swabs was low to 
identify VRE colonization.25 Therefore, we cannot exclude 
the possibility that some colonized patients were not detected. 
However, an aim of infection control measures is to prevent 
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present study, VRE was isolated from clinical samples (urine, 
blood culture) only when a high number of rectal swabs were 
present (Figure S5). Furthermore, each patient with VRE 
in urine and blood culture exhibited VRE in corresponding 
rectal swabs. Therefore, in our analysis, rectal swabs were 
sufficient in identifying clinically relevant colonization. 
A similar observation had been reported earlier.26 Analysis of 
the screening results showed that nearly all of the colonized 
patients had acquired vanB VRE while residing at ERWIN. 
After ERWIN had been closed due to an outbreak of CKP in 
January 2015, all VRE colonized patients were consequently 
isolated without exceptions to prevent further spread of 
VRE. However, transmission of VRE continued, resulting 
in acquisition of VRE by up to six patients per month. Due 
to the preceding CKP outbreak in January 2015, infection 
control measures were consistently performed and the staff 
was very motivated to avoid mistakes. As these efforts failed, 
the consultant at ERWIN started application of S. boulardii 
and E. coli Nissle for all patients treated with antibiotics. 
Subsequently, the number of vanB VRE colonized patients 
continuously decreased in the following months and from 
May 2016 on there were no patients colonized with vanB 
VRE. Most likely, the application of probiotics successfully 
contributed to limiting the spread of vanB VRE, while inten-
sified isolation of VRE colonized patients proved insufficient.
In October 2016 an outbreak of vanA VRE occurred. We 
assumed that due to limitation of vanB VRE spread, the staff 
did not perform basic hygiene measures as intensely as before. 
In total, eleven vanA VRE colonized patients were identified 
in autumn 2016 suggesting acquisition of the bacteria by ten 
patients. However, upon reviewing screening results, as well 
as PFGE analysis, it was revealed that at most, three patients 
acquired the bacteria at ERWIN. Nevertheless, this scenario 
showed that application of probiotics does not substitute the 
need for basic infection control measures. In contrast to long-
lasting spread of vanB VRE within the non-probiotic period, 
spread of vanA VRE was rapidly limited indicating that appli-
cation of probiotics was supportive for limiting the outbreak.
Surprisingly, a decreased number of vanB VRE at 
ERWIN in 2016 was accompanied by a decreased number 
of vanB VRE on the other wards. In the hospital, patients 
are usually moved from other wards to ERWIN but not 
the other way around. While the nursing staff is assigned 
exclusively to ERWIN, speech and physiotherapists visiting 
ERWIN are working on several wards. On the other hand, 
it is not conclusive that the decreased transmission of VRE 
via therapists was a consequence of probiotic treatment of 
patients. Therefore, we have no mechanistic model to explain 
this parallel development. A solution for this situation may be 
to regard VRE transmission not as a single event caused by 
another event, but as a current which depends on the voltage 
of the electric circuit. In such a model a high number of VRE 
colonized patients would represent the force (voltage) driving 
transmission of VRE to another patient. Consequently, a 
high number of VRE will lead to an increased probability of 
VRE acquisition. Apart from the driving force, the number 
of transmissions will also depend on the resistor. In our case, 
a parallel circuit comprising of two resistors seems to be 
present, with ERWIN being resistor 1 and the other wards 
resistor 2. Upon increasing the resistance of one resistor, 
the current in the whole circuit decreases as observed in 
the present scenario. Although the resistance of the second 
resistor will remain unchanged, the current flowing through 
resistor 2 will subsequently decrease because the voltage 
of the circuit has been lowered due to a lower number of 
colonized patients. On the other hand, the number of VRE 
has increased in Germany over the past several years, most 
likely leading to a higher number of VRE colonized patients 
admitted at German hospitals.16,27 This general increase 
explains why the number of vanA and vanB VRE colonized 
patients increased in 2017 on the other wards.
Two of the three vanB VRE strains isolated at the 
ward in autumn 2014 were present after the reopening in 
February 2015. When considering VRE transmission as a 
result of a certain infection control failure this finding can 
only be explained by the assumption that unidentified mem-
bers of the staff had been a VRE reservoir. However, in this 
case there would be no explanation as to why consumption 
of probiotics stopped VRE transmission, despite the reservoir 
still being present on the ward. In contrast, according to the 
electric circuit model of VRE transmission, a reservoir some-
where in the hospital will drive VRE transmission at ERWIN 
as long as the resistor at the ward remains unchanged.
There are two main reasons why multi-resistant bac-
teria often spread on early rehabilitation wards. First, in 
comparison to other hospitalized patients outside intensive 
care and the haemato-oncologic wards, patients at ERWIN 
receive more (broad spectrum) antibiotics. Patients at 
ERWIN mostly suffer from stroke, often regurgitating food, 
especially when fed by their relatives with non-appropriate 
nourishment. Subsequently, the patients develop pneumonia 
and are treated with antibiotics. According to this theory, 
antibiotic treatment was previously identified as the major 
risk factor for acquisition of multi-resistant bacteria.16,28 
Second, patients at ERWIN have more contact with staff 
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often more intensive than contact experienced by patients on 
other wards. However, physiotherapeutic treatment regime 
remained unchanged within the study period. Since the 
number of VRE transmissions decreased despite therapists 
continuing to work with the patients, it is not likely that 
spread of VRE predominantly resulted from this contact. 
Therefore, it is most likely that the application of probiotics 
prevented colonization with VRE by moderating the effect 
of antibiotic treatment on patients’ microbiota.
It is not clear whether the beneficial effect was exclusively 
mediated by the microorganisms or by other components of 
the preparations. Apart from E. coli Nissle, Mutaflor contains 
the laxative, macrogol, which might facilitate the action of 
the microorganisms. It is also not clear whether one of the 
probiotics mediated the beneficial effect alone or if both 
species worked together. There exists only one study in which 
E. coli Nissle was used to limit preexisting VRE colonization 
of mice. In that study E. coli Nissle failed to reduce the VRE 
density.29 In other studies lactobacilli had predominantly been 
used to clear VRE colonization. Although in some studies no 
beneficial effect was observed, in most studies application 
of lactobacilli at least reduced VRE burden, while in some 
examinations VRE was eradicated.30 Conflicting results were 
observed when applying lactobacilli to mice and humans. 
While Lactobacillus rhamnosus Lcr35 lowered VRE density 
in mice there was no effect in VRE colonized patients.29 
Apart from lactobacilli Barnesiella sp. and Bacteroides 
thetaiotaomicron reduced the density of intestinal VRE in 
mice, raising the question whether anaerobic bacteria might 
also be effective probiotics.31,32 Interestingly, Bacteroides 
recovery after antibiotic treatment was facilitated by applying 
Lactobacillus paracasei CNCM I-3689 to VRE (E. faecalis) 
colonized mice.33
Various mechanisms that mediate probiotic benefits 
against VRE have been discussed.30 For instance, 
L. rhamnosus strain GG expresses pili competing with 
those of VRE for mucus binding sites.34 Probiotics were also 
shown to stimulate enteral immunity. From Lactobacillus 
plantarum WCFS1 derived extracellular vesicles protected 
Caenorhabditis elegans against VRE infection perhaps 
increasing the transcription rate of the host defense proteins 
cpr-1 and clec-60.35 In mice, L. paracasei CNCM I-3689 
supplementation increased ileal expression of cathelicidin 
antimicrobial peptide.33
While in most of the analyses probiotics mediated 
beneficial effects, application of a probiotic multi-species 
cocktail coincided with an extended VRE outbreak 
happening between February 2012 and August 2013 at a 
Turkish neonatal intensive care unit.36 Recently, the Drug 
Commission of the German Medical Association (AKDA) 
published a Dear-doctor-letter restricting the usage of 
S. boulardii/Saccharomyces cerevisiae due to occurrence 
of severe infections caused by these microorganisms in 
critically ill patients.37
At ERWIN, probiotics were applied for more than 2 years 
in patients treated with antibiotics. During this time, no 
patient developed infection caused by S. boulardii. However, 
in blood cultures from four patients, multi-susceptible 
E. coli was isolated. Since molecular analyses compar-
ing those isolates with probiotic E. coli Nissle were not 
performed, it remains speculative if two of these infections 
were actually caused by the probiotic E. coli.
In December 2016 VRE screening was terminated. The 
reason for the termination was that rehabilitation depart-
ments and nursing homes were refusing care for patients 
colonized with multi-resistant bacteria. Within the past years 
the authors contacted the Bavarian Medical Association and 
also the Bavarian health authorities to support treatment 
of VRE colonized patients in those facilities. However, 
neither authority believes it has the expertise for such action. 
Therefore, VRE screening was stopped to avoid systemic 
discrimination of VRE colonized patients.
Limitations
To start, the study is a retrospective analysis and was not 
performed under controlled conditions. We do not know 
with any certainty whether probiotics mediated adverse 
side effects. It seems improbable, however, that probiotic 
microorganisms themselves caused infections as described 
previously. On the other hand, we have no proof of that. 
Furthermore, all patients tolerated probiotic application well.
Conclusion
The results of our study show that application of probiotics 
to patients treated with antibiotics might be supportive to 
contain transmission of VRE from patient to patient. In our 
setting usage of both types of probiotics seemed to be safe.
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Figure S1 Usage of hand disinfectant in two neighboring wards at ingolstadt hospital.
Notes: Two wards of the hospital form a unit with a common base for the nursing staff. eRWin: hand disinfectant usage at eRWin and the neighboring palliative ward. 
all wards: median usage of all two-ward units.
Abbreviation: eRWin, early rehabilitation ward of ingolstadt hospital.
Figure S2 Results of screening analyses examining colonization of patients with vancomycin-resistant Enterococcus faecium (VRe) (1–36) in 2015.
Notes: Patients had been treated at the early rehabilitation ward of ingolstadt hospital (eRWin). Rectal swabs were taken at admission and once per week. 
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Figure S3 number of vancomycin-resistant Enterococcus faecium (VRe) colonized patients treated at ingolstadt hospital between 2013 and 2017.
Notes: (A) number of patients treated on all wards including the early rehabilitation ward of ingolstadt hospital (eRWin). (B) number of patients treated at eRWin. (C) 
number of patients treated on wards other than eRWin. Vancomycin resistance of VRe was mediated either by vana (black bars) or vanB gene or was unknown. 
Abbreviation: W/O, without.
Figure S4 number of vana and vanB vancomycin-resistant Enterococcus faecium (VRe) exhibiting esp and hyl genes (black bars) or not (gray bars).
Notes: VRe had been isolated from patients treated at early rehabilitation ward of ingolstadt hospital (eRWin) or on other wards. Observation period: 2014–2017.
Figure S5 number of vancomycin-resistant Enterococcus faecium (VRe) isolated per month from various body sites within the “screening period” (May 2014 to november 
2016) at early rehabilitation ward of ingolstadt hospital (eRWin).
Notes: Per patient and body site one isolate is shown. VRe was isolated from urine and blood culture only in months with a high incidence indicating that rectal screening 
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Figure S6 Patients exhibiting Escherichia coli in blood culture (BC) during the observation period.
Notes: left panel: in total, seven patients exhibited E. coli in BC. Before probiotic application (32 months), three patients were infected and within the period (28 months) 
four patients (1–4). Right panel: bacteriologic findings and the period of antibiotic/probiotic treatment of patients 1–4. The x-axis shows the days of the corresponding 
months from the left panel figure. Concentration of bacteria in urine was .100,000/µl or 10,000–100,000/µl (urine in gray letters). Tazobac: piperacillin/tazobactam. Multi-
susceptible E. coli in high concentration (at least 10,000–100,000/µl) was found in urine from patients 1–3, indicating that the patients already had a problem with E. coli 
before probiotics were applied. Patient 2 had not been treated with probiotics before isolation of E. coli from BC. Patient 3 had a Billroth 2 surgery before admission at early 
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